Literature DB >> 6686776

[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].

W Löffler, W Gröbner, N Zöllner.   

Abstract

The effects of a fixed combination of 100 mg allopurinol and 20 mg benzbromarone (Acifugan) on plasma and urinary uric acid were compared with those of 300 mg allopurinol alone during standardized dietary conditions (purine-free, isoenergetic formula diet with addition of 2 g ribonucleic acid per day). In addition, the components of the fixed combination were given separately. Diet and ribonucleic acid were taken by healthy volunteers for periods of 14 days, drugs were added from day 8 to day 14. Steady state uric acid values before and during drug ingestion were compared intraindividually to calculate drug effects. The fall of plasma uric acid was not significantly different during treatment with 300 mg allopurinol as compared with combined low dose treatment. Renal uric acid excretion was decreased by 56 and 23%, respectively. Comparing combined low dose treatment with the cumulative effects of its constituents it was found that combined treatment was less effective. With combined low dose treatment there is no need to observe prophylactic measures concerning complications at the site of the urinary tract. Compared with monotherapy with 300 mg allopurinol there is no advantage. However, the frequencies of side effects, which are not dose-dependent, will be cumulative with combined treatment, which is probably a major disadvantage. Combined treatment should not be used therefore with the exception of proven inefficiency of monotherapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6686776

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

2.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

Review 4.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  A study of dose-response relationships of allopurinol in the presence of low or high purine turnover.

Authors:  W Löffler; W Gröbner
Journal:  Klin Wochenschr       Date:  1988-02-15

Review 6.  Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Authors:  Garry G Graham; Sophie L Stocker; Diluk R W Kannangara; Richard O Day
Journal:  Curr Rheumatol Rep       Date:  2018-06-21       Impact factor: 4.592

7.  [Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].

Authors:  A Hesse; W Schneeberger; W Vahlensieck
Journal:  Klin Wochenschr       Date:  1987-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.